Join the ChemPartner team for an inspiring lunch seminar!

Here, you'll be presented current approaches and technologies in drug discovery within oncology and neuroscience research. The programme brings together perspectives on how different preclinical strategies and model systems support drug development from early discovery through IND.

Key aspects of antibody–drug conjugate (ADC) development will be covered, including considerations related to efficacy, safety, and resistance. Approaches to improving targeting, stability, and overall therapeutic performance will be outlined, alongside examples from ongoing research programmes.

The meeting will also address challenges in central nervous system (CNS) drug discovery, focusing on how different experimental models are used to study disease mechanisms and evaluate drug candidates. Particular attention will be given to the role of in vitro systems, organoid models, and in vivo studies in generating translationally relevant data.

Overall, the event provides an overview of how combined methodologies and platforms support decision-making and progression in modern drug discovery.

Date, Time & Location: May 19, 11.30–13.30 at Novum Forskningspark, ground floor.

Speakers:

Yinfei Yin, Senior Vice President and Head of Biology, BD, and Marketing.

Feng Ruiben, Principal Scientist of Neurobiology and Neuropharmacology and IACUC Chairperson at ChemPartner, Executive Director of Biology and Pharmacology and IACUC Chairman at Shanghai ChemPartner.

Takashi Willebrand, Associate Director Business Development Nordics.

Lunch and coffe is served for registered participants.

Welcome!